Vericel (VCEL) EV to EBITDA (2010 - 2026)
Analysis
Vericel (VCEL) EV to EBITDA (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Vericel | 2.05 Bn | 1.89 Bn | 56.40 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4,871.19 |
| Mar 31, 2026 | -185.47 |
| Dec 31, 2025 | 75.19 |
| Sep 30, 2025 | 421.86 |
| Jun 30, 2025 | -1,000.19 |
| Mar 31, 2025 | -166.46 |
| Dec 31, 2024 | 141.18 |
| Sep 30, 2024 | -803.13 |
| Jun 30, 2024 | -354.71 |
| Mar 31, 2024 | -441.39 |
| Dec 31, 2023 | 125.18 |
| Sep 30, 2023 | -295.24 |
| Jun 30, 2023 | -283.69 |
| Mar 31, 2023 | -155.76 |
| Dec 31, 2022 | 184.90 |
| Sep 30, 2022 | -144.98 |
| Jun 30, 2022 | -119.61 |
| Mar 31, 2022 | -233.59 |
| Dec 31, 2021 | 419.94 |
| Sep 30, 2021 | -440.22 |